Envestnet Asset Management Inc. raised its position in Novartis AG (NYSE:NVS) by 3.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 621,146 shares of the company’s stock after buying an additional 19,704 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Novartis were worth $53,327,000 at the end of the most recent quarter.
A number of other hedge funds have also recently added to or reduced their stakes in the business. WFG Advisors LP lifted its position in shares of Novartis by 38.1% in the 2nd quarter. WFG Advisors LP now owns 1,221 shares of the company’s stock worth $102,000 after purchasing an additional 337 shares during the period. Cable Hill Partners LLC lifted its position in shares of Novartis by 588.8% in the 3rd quarter. Cable Hill Partners LLC now owns 1,295 shares of the company’s stock worth $112,000 after purchasing an additional 1,107 shares during the period. Harding Loevner LP acquired a new position in shares of Novartis in the 2nd quarter worth approximately $146,000. Mosaic Family Wealth LLC increased its stake in shares of Novartis by 6.1% in the 2nd quarter. Mosaic Family Wealth LLC now owns 2,144 shares of the company’s stock valued at $179,000 after acquiring an additional 123 shares in the last quarter. Finally, Barrett Asset Management LLC increased its stake in shares of Novartis by 650.0% in the 2nd quarter. Barrett Asset Management LLC now owns 2,250 shares of the company’s stock valued at $188,000 after acquiring an additional 1,950 shares in the last quarter. 10.87% of the stock is currently owned by hedge funds and other institutional investors.
Several research firms have recently issued reports on NVS. BidaskClub lowered shares of Novartis from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. Cowen set a $90.00 price objective on shares of Novartis and gave the stock a “hold” rating in a research report on Wednesday, August 9th. J P Morgan Chase & Co restated a “neutral” rating on shares of Novartis in a research report on Tuesday, September 26th. Barclays cut shares of Novartis from an “equal weight” rating to an “underweight” rating in a research report on Wednesday, October 25th. Finally, Leerink Swann increased their price objective on Novartis from $89.00 to $91.00 and gave the company a “market perform” rating in a research note on Monday, October 23rd. Three investment analysts have rated the stock with a sell rating, ten have given a hold rating and four have given a buy rating to the stock. Novartis has an average rating of “Hold” and a consensus price target of $85.32.
Novartis (NYSE:NVS) last released its earnings results on Tuesday, October 24th. The company reported $1.29 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.25 by $0.04. The firm had revenue of $12.41 billion for the quarter, compared to the consensus estimate of $12.21 billion. Novartis had a return on equity of 15.77% and a net margin of 13.73%. The company’s revenue for the quarter was up 2.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.23 EPS. equities research analysts expect that Novartis AG will post 4.75 EPS for the current fiscal year.
WARNING: “Envestnet Asset Management Inc. Acquires 19,704 Shares of Novartis AG (NVS)” was posted by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://www.com-unik.info/2017/12/04/envestnet-asset-management-inc-acquires-19704-shares-of-novartis-ag-nvs.html.
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).
What are top analysts saying about Novartis AG? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Novartis AG and related companies.